Private financing round-up: Aqemia, Hemispherian, Anokion, Salu, VectorBuilder Biotechnology

Hong Kong: VectorBuilder Biotechnology (Guangzhou), a gene delivery enterprise, has completed its Series C round at CNY410m (US$56.6m). The fund raising was co-led by Legend Capital. Proceeds will facilitate VectorBuilder in upgrading and capacity expansion of the gene delivery R&D and production technology platform, accelerate the global business presence, and boost the R&D of life…

You must be a HMI Subscriber to view this content.

Subscribe Now »